Oxidative Stress and Bisphenol A (BPA) Impact With Polycystic Ovary Syndrome (PCOS)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Both oxidative stress and Bisphenol A (BPA) had been associated with polycystic ovary syndrome (PCOS). BPA, one of endocrine-disrupting chemicals (EDCs), is an environmental estrogen used in the synthesis of plastics, is a "high-volume production" chemical with widespread human exposure. BPA was been reported in several female reproductive disturbance. However, the pathological pathway of BPA impact on female reproductive system had not been well-understood. Reactive oxygen species (ROS) have a role in the modulation of gamete quality and gamete interaction. Persistent and elevated generation of ROS leads to a disturbance of redox potential that in turn causes oxidative stress (OS). The first part of The investigators study is aim to evaluate the oxidative stress impact on the biochemical parameters in women with PCOS; the secondary part of the investigators study is to investigate the BPA on the clinical and biochemical of women with PCOS; finally, the investigators plan to test the hypothesis that BPA might increase oxidative stress and then elevated ROS in women with menstrual disturbance, furthermore, the role of oxidative stress and BPA impact on insulin resistance and metabolic disturbance will be also investigated.
Study and control cases will be included. Serum total oxidant status (TOS), total antioxidant status (TAS), Bisphenol A (BPA), and clinical/biochemical parameters will be obtained for all cases. Oxidative stress and BPA will be evaluated with all clinical/biochemical parameters for all subjects.
| Condition |
|---|
|
Oxidative Stress Endocrine-Disrupting Chemicals Polycystic Ovary Syndrome |
| Study Type: | Observational |
| Study Design: | Observational Model: Cohort Time Perspective: Prospective |
| Official Title: | Oxidative Stress and BPA Impact With PCOS |
| Estimated Enrollment: | 300 |
| Study Start Date: | March 2012 |
| Estimated Study Completion Date: | March 2013 |
| Groups/Cohorts |
|---|
| Gruop 1 |
| Group 2 |
Eligibility| Ages Eligible for Study: | 18 Years to 45 Years |
| Genders Eligible for Study: | Female |
| Accepts Healthy Volunteers: | Yes |
| Sampling Method: | Probability Sample |
Normal health control and Women with reproductive endocrine disturbance menstrual irregularity, and/or polycystic ovary syndrome.
Inclusion Criteria:
- Normal health control
- Women with reproductive endocrine disturbance menstrual irregularity, and/or polycystic ovary syndrome.
Exclusion Criteria:
The following subjects were excluded from the study and control populations:
- women who experienced menarche less than 3 years prior to the start of the study;
- women who received hormones, antioxidants or drugs for major medical diseases such as diabetes or cardiovascular disease; and
- women who were older than 45.
Contacts and Locations| Taiwan | |
| WanFang Medical Center at Taipei Medical University | Recruiting |
| Taipei City, Taiwan, 110 | |
| Contact: Ming I Hsu, MD 886-2-29307930 ext 2508 hsumingi@yahoo.com.tw | |
| Principal Investigator: Ming I Hsu, MD | |
More Information
No publications provided
| Responsible Party: | Ming-I Hsu, Taipei Medical University WanFang Hospital |
| ClinicalTrials.gov Identifier: | NCT01600872 History of Changes |
| Other Study ID Numbers: | WFH-TMU-PCOS-201112030 |
| Study First Received: | May 15, 2012 |
| Last Updated: | May 16, 2012 |
| Health Authority: | Taiwan: Department of Health |
Keywords provided by Taipei Medical University WanFang Hospital:
|
EDCs PCOS TAS |
TOS ROS Oxidative Stress, Endocrine-Disrupting Chemicals, Polycystic Ovary syndrome |
Additional relevant MeSH terms:
|
Polycystic Ovary Syndrome Ovarian Cysts Cysts Neoplasms Ovarian Diseases Adnexal Diseases |
Genital Diseases, Female Gonadal Disorders Endocrine System Diseases Endocrine Disruptors Physiological Effects of Drugs Pharmacologic Actions |
ClinicalTrials.gov processed this record on May 22, 2013